Similar articles

• Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

  Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendörfer A, Beere PA, Watson DJ, Downs JR, de Cani JS. Gotto AM Jr, et al. Eur Heart J. 2000 Oct;21(19):1627-33. doi: 10.1053/euhj.2000.2288. Eur Heart J. 2000. PMID: 10988016 Clinical Trial.
• [Statins in primary prevention of coronary heart disease].

  Paulweber B. Paulweber B. Wien Med Wochenschr. 1999;149(5-6):129-38. Wien Med Wochenschr. 1999. PMID: 10408004 Review. German.
• Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.

  Walsh J. Walsh J. JAMA. 1999 Feb 3;281(5):416-7; author reply 417-9. JAMA. 1999. PMID: 9952197 No abstract available.
• Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.

  Haq IU, Wallis EJ, Yeo WW, Jackson PR, Ramsay LE. Haq IU, et al. JAMA. 1999 Feb 3;281(5):414; author reply 417-9. JAMA. 1999. PMID: 9952191 No abstract available.
• [Primary and secondary prevention of coronary disease by statins].

  Ferrières J. Ferrières J. Ann Cardiol Angeiol (Paris). 1999 Feb;48(2):128-36. Ann Cardiol Angeiol (Paris). 1999. PMID: 12555337 Review. French.